Zacks.com users have recently been watching Pfizer (PFE) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.

Pfizer is cutting costs, growing its core business, and trading at a deep discount despite looming patent losses and COVID ...

Pfizer (NYSE:PFE) and BioNTech (NASDAQ:BNTX) have gained a positive opinion from the European Medicines Agency’s Committee ...

Pfizer saw a staggering increase in call options trading, with investors snapping up 539,824 contracts, marking a 286% jump ...

While you can't see Buffett's other seven high-yielding dividend stocks in Berkshire's filings, the company, in essence, has ...

Tariffs, and their potential detrimental impacts on vehicle affordability, company profits, global competitiveness, and ...

Axsome is close to a $500m revenue per annum company with potential to achieve >$1bn per annum by 2030. Read the full AXSM stock analysis here.

New capital, maturing pipelines, and a more global R&D mindset are pushing valuations higher, even as competition tightens.

J.W. Cole Advisors Inc. significantly reduced its holdings in Amgen Inc., selling 4,695 shares, which resulted in a 28.9% ...